Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

British Journal of Dermatology

Volumn 171, Issue 1, 2014, Pages 137-147

  Kimball, A B ^a   Leonardi, C ^b   Stahle, M ^c   Gulliver, W ^d   Chevrier, M ^e   Fakharzadeh, S ^e   Goyal, K ^e   Calabro, S ^e   Langholff, W ^f   Menter, A ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e Janssen Scientific Affairs LLC   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BIOLOGICAL PRODUCT; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; PSORALEN; RETINOID; TAZAROTENE; USTEKINUMAB; DERMATOLOGICAL AGENT; PHOTOSENSITIZING AGENT;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ANXIETY; ARTICLE; ASTHMA; BASAL CELL CARCINOMA; BIOLOGICAL THERAPY; BODY MASS; CARDIOVASCULAR DISEASE; CELIAC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COLITIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMOGRAPHY; DEMYELINATING DISEASE; DEPRESSION; DISEASE DURATION; DISEASE REGISTRY; EUROPE; FAMILY HISTORY; FEMALE; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; LIVER CIRRHOSIS; LONGITUDINAL STUDY; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MELANOMA SKIN CANCER; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTH AMERICA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOTOTHERAPY; PHYSICIAN; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RISK FACTOR; SLEEP DISORDERED BREATHING; SMOKING; SOUTH AND CENTRAL AMERICA; SQUAMOUS CELL CARCINOMA; SUICIDAL IDEATION; THYROID DISEASE; TRANSIENT ISCHEMIC ATTACK; ULCERATIVE COLITIS; ADOLESCENT; AGED; CLINICAL TRIAL; COMPLICATION; HIGH RISK BEHAVIOR; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PATHOLOGY; PEDIGREE; PHOTOCHEMOTHERAPY; REGISTER; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BIOLOGICAL PRODUCTS; BODY MASS INDEX; COMORBIDITY; DERMATOLOGIC AGENTS; EUROPE; FEMALE; HUMANS; LATIN AMERICA; MALE; MIDDLE AGED; NORTH AMERICA; OBESITY; PEDIGREE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; PSORIASIS; REGISTRIES; RISK-TAKING; YOUNG ADULT;

EID: 84905023512     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13013     Document Type: Article

References (53)

1. Griffiths CEM, Barker JNWN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
2. Gladman DD, Antoni C, Mease P, et al,. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. II): ii14-17.
3. Wakkee M, Njisten T,. Comorbidities in dermatology. Dermatol Clin 2009; 27: 137-47.
4. Guenther L, Gulliver W,. Psoriasis comorbidities. J Cutan Med Surg 2009; 13 (Suppl. 2): S77-87.
5. Kim N, Thrash B, Menter A,. Comorbidities in psoriasis patients. Semin Cutan Med Surg 2010; 29: 10-15.
6. Armstrong AW, Harskamp CT, Armstrong EJ,. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2: e54.
7. Armstrong A, Schupp C, Bebo B,. Psoriasis comorbidities: results from the National Psoriasis Foundation Surveys 2003 to 2011. Dermatology 2012; 225: 121-6.
8. Kimball AB, Gladman D, Gelfand J, et al,. National Psoriasis Foundation clinical consensus on psoriasis co-morbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-42.
9. Davidovici BB, Sattar N, Jorg PC, et al,. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 1340: 1785-96.
10. Yeung H, Takeshiti J, Mehta NN, et al,. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013; 149: 1173-9.
11. Kurd SK, Trexel AB, Crits-Christoph P, Gelfand JM,. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-5.
12. Hayes J, Koo J,. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010; 23: 174-80.
13. Ferver K, Burton B, Jesilow P,. The use of claims data in healthcare research. Open Pub Health J 2009; 2: 11-24.
14. Hartz A, Marsh JL,. Methodologic issues in observational studies. Clin Orthop Relat Res 2003; 413: 33-42.
15. Schmitt-Egenolf M,. Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213: 327-30.
16. Papp KA, Strober B, Augustin M, et al,. PSOLAR: Design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012; 11: 1210-17.
17. Gliklich RE, Dreyer NA,. Registries for Evaluating Patient Outcomes: A User's Guide, 2nd edn. Rockville, MD: Agency for Healthcare Research and Quality, 2010.
18. Catanoso M, Pipitone N, Alvarani C,. Epidemiology of psoriatic arthritis. Reumatismo 2012; 64: 66-70.
19. Menter A, Tyring SK, Gordon K,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
20. Lebwohl M, Tyring SK, Hamilton TK, et al,. A novel targeted T-Cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13.
21. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
22. Reich K, Nestle FO, Papp K, et al,. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 355: 1367-74.
23. Menter A, Feldman SR, Weinstein GD, et al,. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-31.e15.
24. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
25. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
26. Bissonnette R, Searles G, Landells I, et al,. The AWARE study: methodology and baseline characteristics. J Cutan Med Surg 2009; 13 (Suppl. 3): S113-21.
27. Kimball AB, Pariser D, Yamauchi PS, et al,. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol 2013; 68: 756-64.
28. Centers for Disease Control and Prevention. QuickStats: prevalence of obesity among persons aged 20-79 years, by sex-Canada, 2007-2009, and United States, 2007-2008. JAMA 2011; 306: 1439.
29. Shipman AR, Millington GWM,. Obesity and the skin. Br J Dermatol 2011; 165: 743-50.
30. Kim GE, Seidler E, Kimball AB,. The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients. J Eur Acad Dermatol Venereol 2014; 28: 216-21.
31. Christophers E,. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 52-5.
32. Takahashi H, Iizuka H,. Psoriasis and metabolic syndrome. J Dermatol 2012; 39: 212-18.
33. Neimann AL, Shin DB, Wang X, et al,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
34. Dreiher J, Weitzman D, Shapiro J, et al,. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol 2008; 159: 956-60.
35. Yang Y-W, Keller JJ, Lin H-C,. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011; 165: 1037-43.
36. Landgren E, Braback L, Hedlin G, et al,. Psoriasis in Swedish conscripts: time trend and association with T-helper 2-mediated disorders. Br J Dermatol 2006; 154: 332-6.
37. Pouplard C, Brenaut E, Horreau C, et al,. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 2013; 27: 36-46.
38. Dommasch E, Gelfand JM,. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 2009; 22: 418-30.
39. Rubin AI, Chen EH, Ratner D,. Basal-cell carcinoma. N Engl J Med 2005; 353: 2262-9.
40. Archier E, Devaux S, Castela E, et al,. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systemic literature review. Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 22-31.
41. Miele L, Vallone S, Cefalo C, et al,. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-86.
42. Madanagobalane S, Anandan S,. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: A study from South India. Aust J Dermatol 2012; 53: 190-7.
43. Dogra S, Mahajan R,. Systemic methotrexate therapy for psoriasis: past, present, and future. Clin Exp Dermatol 2013; 38: 573-88.
44. Bernstein CN, Wajda A, Blanchard JF,. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterol 2005; 129: 827-36.
45. Lees CW, Barrett JC, Parkes M, et al,. New IBD genetics: common pathways with other diseases. Gut 2011; 60: 1739-53.
46. Cohen AD, Dreiher J, Birkenfeld S,. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009; 23: 561-5.
47. Tyring S, Gottlieb A, Papp K, et al,. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 2006; 367: 29-35.
48. Langley RG, Feldman SR, Han C, et al,. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-65.
49. Feldman SR, Gottlieb AB, Bala M, et al,. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008; 159: 704-10.
50. Menter A, Augustin M, Signorovitch J, et al,. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010; 62: 812-18.
51. Menter A, Gottlieb A, Feldman SR, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-50.
52. Fortes C, Mastroeni S, Leffondre K, et al,. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005; 141: 1580-4.
53. Gulliver WP, MacDonald D, Gladney N, et al,. Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador Founder population. J Cutan Med Surg 2011; 15: 37-47.